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Abstract  
Although multiple myeloma has historically been treated with chemotherapy, prolonged 
survival has only been possible since the introduction of thalidomide, lenalidomide and bortezomib. 
However, multiple myeloma remains largely incurable and new treatments are needed to improve 
long-term outcome.  
Elotuzumab is a humanized IgG1 monoclonal antibody that targets Signaling Lymphocyte 
Activation Molecule Family member 7 (SLAMF7) to activate natural killer cells, enabling selective 
killing of myeloma cells with minimal effects on normal tissue. The combination of elotuzumab with 
anti-myeloma therapies that stimulate host immunity may be an attractive treatment option for patients 
with newly diagnosed or relapsed/refractory multiple myeloma. Here we review the role of SLAMF7 in 
the pathogenesis of multiple myeloma and the preclinical and clinical development of elotuzumab. 
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Introduction 
Multiple myeloma is a neoplasm that results in the accumulation of monoclonal plasma cells, 
predominantly in the bone marrow, which interfere with the production of normal white blood cells, red 
blood cells and platelets [1]. It is the second most common hematological cancer after lymphoma [1], 
with an estimated incidence rate of 8 per 100,000 people and an estimated mortality rate of 2.2 per 
100,000 people in Europe in 2012 [2]. Multiple myeloma remains largely incurable using current 
treatment approaches with fewer than 50% of patients surviving five years after diagnosis [3].  
Treatment for multiple myeloma depends on the type and stage of disease, as well as the 
patient’s general health. Melphalan, a nitrogen mustard alkylating agent, administered with 
prednisone, has been used since the 1960s [4], with the combination of high-dose chemotherapy 
(HDC) and autologous stem cell therapy (ASCT) introduced in the 1980s [5]. However, long-term 
survival with these approaches is rare and most patients who initially respond to treatment eventually 
relapse [6]. Upon progression, multiple myeloma is a debilitating malignancy characterized by 
bleeding, infection, bone destruction (including pathological fractures and spinal cord compression), 
anemia, elevated calcium and renal insufficiency or failure [1]. 
The introduction of immunumodulatory therapies and proteosome inhibitors such as 
thalidomide, its amino-substituted analogue lenalidomide, bortezomib [7], carfilzomib and 
pomalidomide have helped delay the onset of progressive disease. These agents, when used alone 
or as part of a combination strategy, have all improved survival compared with controls in phase III 
trials and have consequently been approved for use [8–14] (carfilzomib approved in the US only). 
Thalidomide is indicated in combination with melphalan and prednisone as a first-line treatment for 
patients aged 65 years or older, or patients ineligible for HDC [15]. Lenalidomide was approved in 
combination with dexamethasone for adult patients who have received at least one prior therapy; 
however, this has recently been expanded to include patients with newly diagnosed MM [16], while 
bortezomib monotherapy is indicated for patients with relapsed/refractory MM. and in combination 
with melphalan and prednisone for adult patients with previously untreated multiple myeloma [17]. 
Carfilzomib (US only) and pomalidomide have also been granted approval in patients who have 
received at least two prior lines of therapy [18, 19]. Interestingly, recent studies have shown that 
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treatment with lenalidomide plus conventional chemotherapy significantly reduces the risk of 
progression in newly diagnosed, young multiple myeloma patients aged <65 years [20], potentially 
providing an alternative treatment option for a patient group that typically receive HDC plus ASCT as 
standard. In addition, a meta-analysis of 1435 patients treated across four European phase III trials 
that included thalidomide and/or bortezomib-containing treatment arms showed that being ≥75 years 
of age or having renal failure at presentation, and the occurrence of cardiac, infective or 
gastrointestinal adverse events (AEs) negatively affected survival. This suggests that appropriate 
screening for vulnerability, assessment of organ function and less-intense treatment approaches 
should be considered in frail and elderly multiple myeloma patients to improve tolerability and 
optimize efficacy [21].  
Although the introduction of new agents and use of ASCT has improved the overall survival 
(OS) of patients with multiple myeloma, nearly all patients will experience acquired resistance leading 
to disease relapse. In addition, patients refractory or intolerant to these agents, such as those 
ineligible for SCT, have a poor median OS (9–10 months) [22–24].  
The development of resistance over the course of treatment is thought to arise from a number 
of mechanisms. These include the selection and persistence of resistant multiple myeloma cancer cell 
subclones, cytogenetic and epigenetic alterations and deregulated signaling pathways [25]. 
Furthermore, a number of immunosuppressive mechanisms in the bone marrow and tumor micro-
environment can hamper anti-myeloma immunity approaches by shielding such clones, resulting in 
relapse or disease progression [25]. Alteration of immune cells, including T cells, B cells, natural killer 
(NK) cells and dendritic cells, has also been described in multiple myeloma, leading to a loss of tumor 
immunosurveillance and providing protection to targeted cell death [26, 27].   
Ongoing studies have shown promising outcomes with triplet treatment combinations, 
compared with doublet combinations in terms of progression-free survival (PFS), possibly due to the 
multiple mechanisms of action that are employed when three agents are administered concurrently. 
For example, median PFS with carfilzomib in combination with lenalidomide and dexamethasone has 
been shown to be 26.3 months, compared with 17.6 months in patients treated with lenalidomide and 
dexamethasone only [28]. Nevertheless, given the heterogeneous nature of the oncogenic processes 
involved in multiple myeloma and the immunosuppressive mechanisms that play a critical role in 
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myeloma tumor cell survival and environment-mediated drug resistance [25], there is a further need 
for a combined treatment modalities approach, which should include an element that effectively 
targets the immune system [29, 30]. Combined treatment modalities may enable sustained complete 
responses in a significant number of patients, in particular if therapy is given during the early phases 
of disease or early relapse, before disease-related immune dysfunction and multiple courses of 
treatment negatively impact the patient’s immune function [31–33]. Furthermore, tolerability of 
treatment-related toxicities may also be better during early treatment, especially in ASCT-ineligible 
patients [31]. 
One approach to developing myeloma-selective therapy has been the investigation of 
monoclonal antibodies (mAbs) targeting antigens expressed exclusively or predominantly on multiple 
myeloma cells. Antigens may include those involved in cell survival, antiapoptotic pathways,  
cell-to-cell communication, angiogenesis and interactions between multiple myeloma cells in the 
tumor and bone marrow microenvironment. The mechanisms of action of mAbs include both direct 
tumor cell destruction, and indirect mechanisms such as the regulation of immune responses through 
complement-dependent cytotoxicity (CDC) and/or antibody-dependent cell-mediated cytotoxicity 
(ADCC) [34]. Elotuzumab, is a humanized mAb that targets the antigen Signaling Lymphocyte 
Activation Molecule Family member 7 (SLAMF7), expression of which is largely restricted to 
neoplastic plasma cells and NK cells as opposed to other, normal tissues. This review focuses on the 
role of SLAMF7 in the pathogenesis of multiple myeloma and the preclinical and clinical development 
of elotuzumab, and discusses the role of this mAb in combination with other multiple myeloma 
therapies. 
 
Preclinical Rationale 
SLAMF7 is a glycosylated cell surface protein and a member of the SLAM (signaling 
lymphocyte activation molecules) family [35]. It was first identified on NK cells, mediating their 
adhesion and function through a self-ligand binding interaction [36, 37]. Self-engagement of SLAMF7, 
or engagement by SLAMF7-specific antibodies, leads to association with its adaptor protein (EAT-2), 
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resulting in enhanced activation of NK cells, promoting their ability to mediate killing of target cells 
through the subsequent release of cytotoxic granules [37, 38]. 
Using a subtractive hybridization approach, Hsi and colleagues demonstrated that the 
SLAMF7 gene was highly expressed in plasma cells [39]. This was confirmed by gene expression 
profiling that showed high SLAMF7 expression in plasma cells from healthy donors, with lower 
expression in NK cells and normal non-lymphoid tissues [39]. Importantly, SLAMF7 mRNA was highly 
expressed across the various molecular subtypes of myeloma, including all cytogenetic risk groups. 
Indeed, an analysis of bone marrow plasma cells collected from multiple myeloma patients showed 
that the SLAMF7 protein was expressed in all samples, with 19/20 samples having >75% expression 
of SLAMF7 [39]. In a separate analysis, low but detectable levels of soluble SLAMF7 (sSLAMF7) 
were found in the sera of some patients with multiple myeloma, while sSLAMF7 was not present in 
healthy donor sera [40]. Although there was no correlation between SLAMF7 surface expression and 
disease stage, patients with advanced stage or symptomatic multiple myeloma (International Stage 
Systems [ISS] II/III) had significantly higher levels of sSLAMF7 than those with ISS I, suggesting that 
sSLAMF7 may represent a biomarker of disease progression [40].  
SLAMF7 is highly expressed in benign and neoplastic plasma cells, expressed at lower levels 
on the surface of NK cells, is infrequently expressed in the parenchyma of any major organs and is 
not found on hematopoietic stem cells [37, 39], making it a unique protein for the therapeutic targeting 
of multiple myeloma cells. Consequently, the humanized monoclonal immunoglobulin G1 antibody 
elotuzumab, which targets SLAMF7, was developed. 
 
Mechanism of Action 
The primary mechanism of action of elotuzumab is the lysis of multiple myeloma cells via 
ADCC (Figure 1), a process initially thought to be dependent on the presence of NK cells or other 
peripheral blood mononuclear cells (PBMCs) [39, 40]. However, as depletion of T cells, B cells or 
monocytes from a PBMC effector cell population had no effect on elotuzumab-induced ADCC, it was 
suggested that the lytic activity of elotuzumab is primarily mediated by NK cells [39]. Indeed, 
Elotuzumab development  7 
elotuzumab binds to SLAMF7 on multiple myeloma cells, while also binding to CD16 on NK cells, 
activating NK cells to lyse the antibody-bound tumor cells [41]. It is has also been shown that 
elotuzumab directly activates NK cells by binding to SLAMF7 on their surface and enhances their anti-
myeloma activity via interaction with the signaling intermediary EAT-2, which is present in NK cells but 
absent in primary, human multiple myeloma cells [38, 41]. Interestingly, in vivo treatment with 
elotuzumab resulted in the lysis of multiple myeloma cells from patients who were resistant to 
conventional therapies [40]. There are other proposed mechanisms by which elotuzumab could target 
multiple myeloma cells [41–43]. For example, it has been suggested that elotuzumab may impair the 
adhesion of SLAMF7-expressing multiple myeloma cells to bone marrow stromal cells (BMSCs) [40]. 
This proposal was supported by in vitro studies in which the downregulation of SLAMF7 by a lentiviral 
short interfering RNA line prevented human multiple myeloma cells from binding to cultured BMSCs 
[40]. 
 
Early Clinical Experience 
On the basis of promising preclinical results, elotuzumab was evaluated as monotherapy in a 
phase I, dose-escalation trial (Table 1) [44–47]. Patients with relapsed or refractory multiple myeloma 
were treated with intravenous elotuzumab at one of six dose levels (0.5 to 20 mg/kg) once every 14 
days for 8 weeks, with the option of a second course of treatment in patients without relapse [44]. 
Study endpoints included safety, tolerability and pharmacokinetic profile. Elotuzumab was generally 
well tolerated. Most treatment-related AEs were grade 1 or 2 in severity, with the most common 
(>10% of patients) including chills, pyrexia and flushing (Table 2) [44–48]. The maximum tolerated 
dose was not reached. Infusion-related events were observed in 20 (59%) patients although these 
were mitigated after the protocol was amended to include premedication before the first elotuzumab 
dose. Although no objective responses were observed, 9/35 (26%) heavily-pretreated patients had 
stable disease according to the European Group for Blood and Marrow Transplantation myeloma 
response criteria [44]. 
 
Elotuzumab development  8 
Elotuzumab-Based Combination Therapy  
Preclinical rationale 
The relatively modest antitumor activity of elotuzumab monotherapy may be attributable to 
immunosuppressive effects. Multiple myeloma cells have a unique ability to elude immunosurveillance 
due to both dendritic cell and regulatory T cell abnormalities, and the secretion of immunoregulatory 
cytokines (e.g. by BMSCs) into the tumor microenvironment [49]. In addition, multiple myeloma is 
associated with decreased NK cell function and an increase in the number of immunosuppressive 
myeloid-derived suppressor cells in peripheral blood and bone marrow [50, 51].  
Due to its distinct mechanism of action, elotuzumab is likely to act synergistically with treatment 
modalities that stimulate host anti-myeloma immunity; therefore, combination approaches may be 
more effective than single-agent therapy. For example, combination with lenalidomide or thalidomide 
may improve clinical benefit as these agents alter cytokine production and enhance T- and NK-cell-
mediated immune responses [52, 53]. In addition, as proteasome inhibition stimulates apoptosis, 
reduces angiogenesis, cytokine signaling and cell adhesion, and can increase the susceptibility of 
multiple myeloma cells to NK cell-mediated killing [54, 55], combination with bortezomib may also be 
effective [56, 57]. In preclinical studies, overnight pretreatment of multiple myeloma cells with 
dexamethasone, bortezomib, lenalidomide or perifosine (an Akt inhibitor) enhanced elotuzumab-
induced lysis of multiple myeloma cells (Figure 2) [40]. Furthermore, in a mouse model of multiple 
myeloma, the combination of elotuzumab with bortezomib significantly increased in vivo antitumor 
activity compared with elotuzumab alone [58]. 
An alternative strategy could be to combine elotuzumab with mAbs that augment antitumor 
immune responses through indirect modulation of immune regulatory checkpoints. Possible 
combination partners include inhibitors of programmed death 1 and cytotoxic T-lymphocyte-
associated antigen-4 or CD137 agonists [49, 59–61]. This approach is supported by results from 
xenograft transplant models of breast cancer, where stimulation of NK cells with agonistic CD137 
antibodies enhanced the efficacy of the ADCC-mediating mAb trastuzumab [62]. In addition, 
immunostimulation with an agonistic CD137 antibody in mouse models of myeloma has been shown 
to activate NK cells [61].  
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Many other agents have the potential to enhance clinical benefit when combined with 
elotuzumab. For example, NK cell-mediated ADCC is enhanced by administration of monoclonal 
antibodies to inhibitory killer immunoglobulin-like receptors [63]. In addition, compounds that disrupt 
the immunosuppressive microenvironment, for example by modulating the number or function of T 
regulatory cells or indoleamine 2,3-dioxygenase expression [64], may also be valuable combination 
partners.  
 
Clinical experience and ongoing studies 
The combination of elotuzumab with bortezomib or with lenalidomide plus low dose 
dexamethasone has been evaluated in two phase I clinical trials in patients with relapsed or refractory 
multiple myeloma. Among patients treated with elotuzumab plus bortezomib, the objective response 
rates (ORRs) were 48% for all evaluable patients (n = 28) and 67% for patients refractory to 
bortezomib (Table 1). The most frequent grade 3 or 4 AEs were lymphopenia (25% of patients) and 
fatigue (14%) (Table 2; [45]). During the study, the protocol was amended to include patients with no 
prior bortezomib treatment and those who were responsive (partial response or better) to prior 
bortezomib treatment for ≥3 months, or who were responsive to prior bortezomib treatment at the time 
of switching to another treatment or ceasing treatment, and excluded patients who had been treated 
with bortezomib less than 3 months before the initial dose [45].  
In a phase IB study of elotuzumab at a dose of 5, 10 or 20 mg/kg with lenalidomide and low-
dose dexamethasone, the ORR was 82% (n = 29) (Table 1) [46]. For the 20 mg/kg cohort, median 
time to progression had not been reached after a median follow-up of 16.4 months. Among all 
patients, the most common grade 3 or 4 treatment-emergent AEs were neutropenia (36%) and 
thrombocytopenia (21%); 89% of patients experienced at least one infusion reaction, although most of 
these resolved either spontaneously or with supportive care (Table 2; [46]). Patients who had 
received prior lenalidomide treatment within the preceding 6 weeks were excluded from the study. 
A phase II trial of elotuzumab at a dose of 10 or 20 mg/kg plus lenalidomide (25 mg) and low-
dose dexamethasone (40 mg) has recently been completed in 73 patients with relapsed or refractory 
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multiple myeloma [47]. The primary objective was ORR (≥ partial response per International Myeloma 
Working Group Criteria), with PFS and safety as key secondary endpoints [47]. The overall ORR was 
84%, comprising 92% of patients treated with 10 mg/kg elotuzumab and 76% patients treated with 20 
mg/kg elotuzumab (Table 1) [47]. Median PFS was 29 months overall, 32 months and 25 months in 
the 10 mg/kg and 20 mg/kg cohorts, respectively. The most common treatment-emergent AEs were 
diarrhea (66%), muscle spasms (62%), fatigue (56%), constipation (51%), nausea (48%), and upper 
respiratory tract infection (47%). Serious AEs were reported in 58% of patients, most commonly 
pneumonia (12%).;  
The overall rate of infusion reactions at study completion was 11% [47]. The most common 
infusion reactions were pyrexia and rash, which occurred in 3 patients each [65]). In order to mitigate 
infusion reactions, patients were premedicated before each elotuzumab infusion. Pretreatment for 
infusion reactions originally included an antihistamine and acetaminophen, which was optional for 
patients who experienced any infusion reaction [46]; during the course of the study, the pretreatment 
regimen evolved considerably, reducing the severity and incidence of infusion reactions [66]. A long-
term safety analysis revealed a consistent safety profile following 18 months of therapy versus the 
safety profile observed within the first 18 months. No new safety signals were identified [48]. Patients 
within the Phase 2 portion of this study were excluded if they had received prior lenalidomide therapy 
(prior lenalidomide was permitted in Phase 1). Based on the results of this study to date, the U.S. 
Food and Drug Administration (FDA) granted elotuzumab Breakthrough Therapy Designation for use 
in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma in 
patients who have received one or more prior therapies. 
Several other elotuzumab-based trials are currently ongoing or recruiting patients (Table 3) [44, 45, 
47, 67–72], the results of which will further enhance the understanding of elotuzumab in multiple 
myeloma. The Phase 3 ELOQUENT-2 trial (NCT01239797) further investigates elotuzumab in 
combination with lenalidomide and dexamethasone in relapsed and refractory patients, using a 
randomized, controlled study design. The Phase 3 ELOQUENT-1 trial (NCT01335399) examines this 
combination as first-line therapy for multiple myeloma. In addition, further research into the biology of 
SLAMF7 in normal and multiple myeloma cells, including in PMBCs other than NK cells, is ongoing.  
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Conclusions and Future Directions 
New therapeutic strategies are still required in multiple myeloma to further prolong remission 
without impacting on safety. Early indications from clinical studies suggest that elotuzumab has 
promise in multiple myeloma, particularly when used in combination with other anti-myeloma 
therapies. Elotuzumab, in combination with lenalidomide plus dexamethasone, has been shown to 
result in a high ORR and extended PFS in patients with relapsed or refractory multiple myeloma with 
no significant overlapping toxicity reported. Results from the two phase III trials (Table 3) will 
determine whether or not the combination should be recommended for patients with either newly 
diagnosed or relapsed/refractory multiple myeloma. Currently, there are no data to support the use of 
elotuzumab in newly diagnosed patients, although several trials are ongoing in this population. 
Because expression of SLAMF7 on multiple myeloma cells has been shown to be independent of 
disease stage, first-line treatment may be effective. In addition, use of immunotherapy earlier in the 
course of the disease may be more beneficial as immune dysfunction is known to become more 
prevalent as the disease progresses [73].  
With continued development, elotuzumab-based regimens have the potential to become an 
integral component of the treatment armamentarium for multiple myeloma; providing hope for even 
better outcomes in the future. 
Expert commentary  
Multiple myeloma is a debilitating malignancy characterized by a chronic series of relapses until 
death. Historically, treatment with melphalan plus prednisone or high-dose chemotherapy plus 
autologous stem cell therapy failed to improve long-term survival and prevent relapse in patients with 
multiple myeloma. However, in recent years, the availability of novel therapies such as the 
immunomodulatory drugs thalidomide and lenalidomide, and the proteasome inhibitor bortezomib, 
has significantly advanced treatment, resulting in improved survival rates and longer remission times. 
Nevertheless, most patients still struggle to achieve therapeutic goals due to patient characteristics 
(eg, older age and ineligibility for stem cell transplantation) and treatment-related toxicities, and 
multiple myeloma remains an incurable disease. Thus, there is an urgent unmet medical need for 
more effective therapies. 
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The optimal goals of multiple myeloma therapy are to prolong survival with minimal toxicity while 
maximizing durability of response and long-lasting symptom relief. To this end, second generation 
novel agents, such as the immunomodulatory drug pomalidomide, and the proteasome inhibitors 
carfilzomib and ixazomib, may build upon the efficacy of first generation agents to improve outcomes 
further. Moreover, as demonstrated by recent and ongoing clinical trials, monoclonal antibodies that 
activate the immune response and target myeloma cells specifically, such as the anti-SLAM7 agent 
elotuzumab, may offer the potential for clinically relevant improvements in outcome in the future, 
particularly considering their good safety and tolerability profile when administered in combination with 
other anti-myeloma therapies.  
Five-year view  
The results of ongoing studies with elotuzumab and other monoclonal antibodies are likely to 
influence treatment of multiple myeloma over the next 5 years. If the results of pivotal trials are 
positive, monoclonal antibodies may become the backbone of multiple myeloma treatment in 
combination with currently available standard therapies, potentially offering improved rates of long-
term survival with acceptable tolerability profiles. In the case of elotuzumab in particular, such 
combinations may also be recommended for patients with newly diagnosed or relapsed/refractory 
multiple myeloma, exploiting the disease stage independence of SLAM7 expression on multiple 
myeloma cells and the benefits of targeting immune dysfunction early in the course of the disease.  
The cost of managing multiple myeloma is significant and extends beyond the price of treatment, 
encompassing the costs associated with disease management and treatment of adverse events. If 
they are proven to significantly improve remission duration and have favourable safety and tolerability 
profiles, monoclonal antibodies such as elotuzumab may also offer pharmacoeconomic benefits, 
although further evidence on the pharmacoeconomic benefits of monoclonal antibodies is still 
required. 
Novel combinations of therapies are another avenue that is likely to be extensively explored in clinical 
trials over the next 5 years. Combining monoclonal antibodies that target tumour cells directly with 
monoclonal antibodies that augment antitumor immune responses through indirect modulation of 
immune regulatory checkpoints is an approach that holds considerable promise. Indeed, inhibitors of 
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programmed death 1 and cytotoxic T-lymphocyte-associated antigen-4, and agonists of CD137 have 
already shown encouraging results in several cancers including multiple myeloma. Several other 
agents also have the potential to enhance clinical benefit when combined with monoclonal antibodies 
that target tumour cells directly, including monoclonal antibodies against inhibitory killer 
immunoglobulin-like receptors and agents that disrupt the immunosuppressive microenvironment. 
Other potential treatment approaches that could be utilized in multiple myeloma to overcome immune 
deficiencies include therapeutic vaccines [74, 75], and chimeric antigen receptor-expressing T cells 
[76, 77]; although further investigations are still needed with these agents. Immune dysfunction is a 
key characteristic of multiple myeloma and, therefore, directly targeting and stimulating the immune 
system is promising treatment of approach. 
Overall, the treatment landscape for multiple myeloma is likely to change significantly over the next 
five years, providing real hope for better outcomes in patients with this debilitating disease. 
Key issues  
 With an estimated incidence rate of 8 per 100,000 people, multiple myeloma is the second 
most common hematological cancer after lymphoma. 
 Although historically treated with chemotherapy, the recent approvals of thalidomide, 
lenalidomide and bortezomib have prolonged survival of patients with multiple myeloma; 
nevertheless, fewer than 50% of patients survive for five years after diagnosis. 
 Therefore, new treatments are urgently required to improve the long-term outlook of such 
patients, particularly those with relapsed multiple myeloma. 
 Elotuzumab is a humanized IgG1 monoclonal antibody that binds to Signaling Lymphocyte 
Activation Molecule Family member 7 (SLAMF7), a glycoprotein expressed by myeloma and 
natural killer cells. 
 The binding of elotuzumab to SLAMF7 activates natural killer cells, but not myeloma cells. 
Elotuzumab bound to myeloma cells via SLAMF7 further activates natural killer cells via a 
CD16 mediated pathway, enabling selective killing of myeloma cells with minimal effects on 
normal tissue 
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 Due to its distinct mechanism of action, elotuzumab is likely to act synergistically with 
treatment modalities that stimulate host anti-myeloma immunity; thus, the combination of 
elotuzumab with anti-myeloma therapies that stimulate host immunity is an attractive 
treatment option, especially early in the course of the disease before disease-related immune 
dysfunction and multiple courses of treatment negatively impact immune function.  
 Indeed, the combination of elotuzumab with bortezomib or lenalidomide plus low dose 
dexamethasone has shown promising activity in two phase I clinical trials in patients with 
relapsed or refractory multiple myeloma; phase III combination trials in patients with newly 
diagnosed or relapsed/refractory multiple myeloma are ongoing. 
 The results of these trials may support the use of elotuzumab-based treatment regimens in 
multiple myeloma. 
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Figure Legends 
 
Figure 1. Mechanism of action of elotuzumab against multiple myeloma cells. 
Elotuzumab enhances NK cell activation, directly via SLAMF7 and indirectly via CD16, and targeted 
killing of SLAMF7+ myeloma cells by ADCC. 
Abbreviations: ADCC, antibody-dependent cell-mediated cytotoxicity; NK, natural killer. 
 
Figure 2. Pretreating multiple myeloma cell lines with conventional therapies significantly enhanced 
elotuzumab-induced ADCC (*P = 0.05; **P = 0.01). Figure adapted with permission from Tai et al [40].  
Abbreviation: ADCC, antibody-dependent cell-mediated cytotoxicity. 
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Figure 1 
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Figure 2
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Table 1. Efficacy of elotuzumab in clinical trials 
Treatment (trial ID) Phase Number of patients ORR, % Median TTP/PFS, 
months 
Reference 
Elotuzumab monotherapy 
(NCT00425347) 
I 35 0 – Zonder et al., 2012 [44] 
Elotuzumab and 
bortezomib 
(NCT00726869) 
I 28 48 9.5
a
 Jakubowiak et al., 
2012 [45] 
Elotuzumab with 
lenalidomide and 
dexamethasone 
(NCT00742560) 
IB 29 82 NR
b
 Lonial et al., 2012 [46] 
Elotuzumab with 
lenalidomide and 
dexamethasone 
(NCT00742560) 
II 
(20 mg/kg cohort) 
37 76 25
b
 Richardson et al., 2014 
[47] 
II 
(10 mg/kg cohort) 
36 92 32 
Abbreviations: ORR, objective response rate; PFS, progression-free survival; TTP, time to progression. 
a
Median TTP; 
b
Median PFS 
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Table 2. Frequent adverse events with elotuzumab in clinical trials 
Treatment (trial ID) Percentage of patients 
with treatment-
related/emergent AEs, 
% 
Treatment-emergent 
AEs, % 
Serious treatment-emergent 
AEs, % 
Reference 
Elotuzumab 
monotherapy 
(NCT00425347) 
Any grade: 53 
Serious AEs: 18 
Chills: 
Pyrexia: 
Flushing:  
Chest discomfort:  
32 
18 
12 
9 
Bradycardia:  
Chest discomfort:  
Chills:  
Hypersensitivity: 
  3 
  3 
  3 
  3 
Zonder et al., 2012 [44] 
Elotuzumab and 
bortezomib 
(NCT00726869) 
Any grade: 100 
Grade 3/4: 79 
Fatigue: 
Anemia: 
Diarrhea: 
Thrombocytopenia: 
82 
71 
71 
68 
Lymphopenia: 
Fatigue: 
Thrombocytopenia: 
Neutropenia: 
25 
14 
11 
11 
Jakubowiak et al., 2012 [45] 
Elotuzumab with 
lenalidomide and 
dexamethasone 
(NCT00742560) 
Serious AEs: 43  
Diarrhea:  
Muscle spasms: 
Fatigue: 
Constipation: 
Nausea: 
Upper RTI: 
 
66 
62 
56 
51 
48 
47 
Neutropenia: 
Thrombocytopenia: 
36 
21 
Lonial et al., 2012 [46] 
Richardson et al., 2014 [47] 
Elotuzumab with 
lenalidomide and 
dexamethasone 
(NCT00742560) 
Grade ≥3 NA  Lymphopenia: 
Neutropenia: 
Thrombocytopenia: 
Anemia 
19 
18 
16 
14 
Lonial et al., 2013 [48] 
 
Abbreviations: AE, adverse event; NA not available; RTI, respiratory tract infection. 
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Table 3. Summary of completed and ongoing elotuzumab clinical trials in multiple myeloma 
Trial ID Study population Design Primary endpoint Number of patients 
Monotherapy trials 
NCT00425347 
(Zonder et al., 2012 
[44]) 
Relapsed/refractory 
multiple myeloma 
Phase I dose-escalation study 
of elotuzumab monotherapy 
 
Safety (MTD) 35 
NCT01441973 High risk smouldering 
myeloma 
Phase II biomarker study of 
elotuzumab monotherapy 
Association between change in 
monoclonal protein and 
percentage of CD56
dim
 NK cells 
40 
Combination therapy trials 
NCT00726869 
(Jakubowiak et al., 
2012 [45]) 
Relapsed/refractory 
multiple myeloma 
Phase I/II dose-escalation 
study of elotuzumab and 
bortezomib 
 
MTD of elotuzumab 28 
NCT00742560 
(Richardson et al., 
2014 [47]) 
Relapsed/refractory 
multiple myeloma 
Phase IB/II dose-escalation 
study of elotuzumab with 
lenalidomide and 
dexamethasone 
Phase I: MTD; phase II: ORR 102 
NCT01668719 
(Usmani et al., 2014 
[67])  
Newly diagnosed high 
risk multiple myeloma 
Phase I/II study of optimal 
induction therapy of 
bortezomib, dexamethasone 
and lenalidomide with or 
without elotuzumab 
PFS 122 
NCT01393964 
(Berdeja et al., 2014 
[68]) 
Newly diagnosed or 
relapsed/refractory 
multiple myeloma 
Phase IB study of elotuzumab 
with lenalidomide and 
dexamethasone in multiple 
PK/PD properties of elotuzumab 26 
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myeloma patients with 
various levels of renal 
function 
NCT01241292 Relapsed/refractory 
multiple myeloma 
Phase I multiple ascending 
dose study of elotuzumab 
with lenalidomide and low-
dose dexamethasone 
Safety and tolerability (DLT) 20 
NCT01632150 
(Mateos et al., 2014 
[69]) 
Relapsed/refractory 
multiple myeloma 
Phase IIA single-arm study of 
elotuzumab with thalidomide 
and dexamethasone 
Proportion of subjects with ≥1 
severe (grade ≥3) non-
hematological AE 
40 
NCT01478048 
(Jakubowiak et al., 
2012 [70]) 
Relapsed/refractory 
multiple myeloma 
Phase II study of bortezomib 
and dexamethasone with or 
without elotuzumab 
PFS 150 
NCT02159365 Newly diagnosed or 
relapsed/refractory 
multiple myeloma  
Phase II single-arm safety 
study of elotuzumab 
administered over ~60 mins 
with lenalidomide and 
dexamethasone  
The percentage of patients with 
G3/4 infusion reactions by the 
end of treatment cycle 2 
76 
NCT01335399 
(ELOQUENT-1) 
(Dimopoulos et al., 
2012 [71]) 
Newly diagnosed, 
previously untreated 
multiple myeloma 
Phase III trial of lenalidomide 
and dexamethasone with or 
without elotuzumab 
PFS (change in expression of 
SLAMF7 will be examined in a 
biomarker sub-study) 
750 
NCT01239797 
(ELOQUENT-2) 
(Lonial et al., 2012 
[72]) 
Relapsed/refractory 
multiple myeloma 
Phase III trial of lenalidomide 
and dexamethasone with or 
without elotuzumab 
PFS 640 
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Abbreviations: AE, adverse event; DLT, dose limiting toxicity; MTD, maximum tolerated dose; NK, natural killer; ORR, objective response rate; PD, 
pharmacodynamic; PFS, progression-free survival; PK, pharmacokinetic. 
 
